X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse STRIDES PHARMA SCIENCE with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs ACTAVIS (US) - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 STRIDES PHARMA SCIENCE   ACTAVIS
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
ACTAVIS
Dec-14
STRIDES PHARMA SCIENCE/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,14719,794-   
Low Rs64212,074-   
Sales per share (Unadj.) Rs317.23,564.4-  
Earnings per share (Unadj.) Rs7.8-444.8-  
Cash flow per share (Unadj.) Rs25.1327.0-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.37,731.1-  
Shares outstanding (eoy) m89.50265.90-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.5 63.1%   
Avg P/E ratio x114.0-35.8 -318.3%  
P/CF ratio (eoy) x35.748.7 73.3%  
Price / Book Value ratio x3.32.1 158.2%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,0584,236,897 1.9%   
No. of employees `0002.521.6 11.6%   
Total wages/salary Rs m4,3410-   
Avg. sales/employee Rs Th11,325.843,878.6 25.8%   
Avg. wages/employee Rs Th1,731.40-   
Avg. net profit/employee Rs Th280.1-5,475.6 -5.1%   
INCOME DATA
Net Sales Rs m28,394947,779 3.0%  
Other income Rs m941-2,365 -39.8%   
Total revenues Rs m29,334945,413 3.1%   
Gross profit Rs m3,965121,756 3.3%  
Depreciation Rs m1,540205,229 0.8%   
Interest Rs m1,96229,895 6.6%   
Profit before tax Rs m1,403-115,733 -1.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436-8,490 5.1%   
Tax Rs m97-5,950 -1.6%   
Profit after tax Rs m702-118,273 -0.6%  
Gross profit margin %14.012.8 108.7%  
Effective tax rate %6.95.1 134.9%   
Net profit margin %2.5-12.5 -19.8%  
BALANCE SHEET DATA
Current assets Rs m24,836499,358 5.0%   
Current liabilities Rs m18,993364,179 5.2%   
Net working cap to sales %20.614.3 144.3%  
Current ratio x1.31.4 95.4%  
Inventory Days Days7158 122.3%  
Debtors Days Days11366 171.1%  
Net fixed assets Rs m34,289115,733 29.6%   
Share capital Rs m8950-   
"Free" reserves Rs m23,6510-   
Net worth Rs m24,5462,055,697 1.2%   
Long term debt Rs m15,5131,077,226 1.4%   
Total assets Rs m65,4373,767,417 1.7%  
Interest coverage x1.7-2.9 -59.7%   
Debt to equity ratio x0.60.5 120.6%  
Sales to assets ratio x0.40.3 172.5%   
Return on assets %4.1-2.3 -173.6%  
Return on equity %2.9-5.8 -49.7%  
Return on capital %6.9-3.0 -229.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m14,9620-   
CASH FLOW
From Operations Rs m1,871162,752 1.1%  
From Investments Rs m5,826-389,691 -1.5%  
From Financial Activity Rs m-10,157218,950 -4.6%  
Net Cashflow Rs m-2,615-7,989 32.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 72.56 Rs / USD

Compare STRIDES PHARMA SCIENCE With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare STRIDES PHARMA SCIENCE With: ALKEM LABORATORIES  TORRENT PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  CADILA HEALTHCARE  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views On News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Oct 1, 2018 | Updated on Oct 1, 2018

Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Nov 13, 2018 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS